172,202 Shares in Replimune Group, Inc. (NASDAQ:REPL) Purchased by Crestline Management LP

Crestline Management LP acquired a new stake in Replimune Group, Inc. (NASDAQ:REPL - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 172,202 shares of the company's stock, valued at approximately $2,085,000. Crestline Management LP owned about 0.25% of Replimune Group at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Boxer Capital Management LLC bought a new stake in shares of Replimune Group in the 4th quarter worth approximately $21,754,000. Price T Rowe Associates Inc. MD grew its position in Replimune Group by 11.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 10,962,883 shares of the company's stock worth $132,761,000 after acquiring an additional 1,083,633 shares during the last quarter. Marshall Wace LLP acquired a new position in Replimune Group in the fourth quarter worth $10,853,000. Wellington Management Group LLP grew its holdings in shares of Replimune Group by 352.5% during the fourth quarter. Wellington Management Group LLP now owns 1,096,744 shares of the company's stock worth $13,282,000 after purchasing an additional 854,346 shares during the last quarter. Finally, Artisan Partners Limited Partnership bought a new stake in Replimune Group during the 4th quarter worth about $7,399,000. Institutional investors own 92.53% of the company's stock.

Replimune Group Stock Down 0.8 %

REPL stock traded down $0.06 during mid-day trading on Friday, reaching $7.71. The company had a trading volume of 1,352,895 shares, compared to its average volume of 899,337. The company has a market capitalization of $593.79 million, a price-to-earnings ratio of -2.51 and a beta of 0.68. Replimune Group, Inc. has a 52 week low of $4.92 and a 52 week high of $17.00. The stock has a 50 day simple moving average of $9.36 and a two-hundred day simple moving average of $11.48. The company has a debt-to-equity ratio of 0.14, a current ratio of 11.43 and a quick ratio of 11.43.

Replimune Group (NASDAQ:REPL - Get Free Report) last released its earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.09). As a group, equities analysts predict that Replimune Group, Inc. will post -2.97 earnings per share for the current fiscal year.

Analyst Ratings Changes

REPL has been the subject of a number of recent research reports. JPMorgan Chase & Co. boosted their price target on shares of Replimune Group from $16.00 to $18.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 26th. BMO Capital Markets increased their price target on Replimune Group from $18.00 to $27.00 and gave the stock an "outperform" rating in a report on Wednesday, January 22nd. Finally, HC Wainwright upped their price target on shares of Replimune Group from $21.00 to $22.00 and gave the company a "buy" rating in a report on Thursday, February 13th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $19.43.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.